April 14, 2016

Sponsored by

Webinar Description:

The Role of Pharmacogenetic Testing in Personalized Medicine, and Challenges Associated with Clinical Implementation. Pharmacogenetics is playing an increasingly important role in personalized medicine, yet it faces a number of challenges when implemented in a clinical setting. In this webinar, Dr. Stuart Scott from the Icahn School of Medicine at Mount Sinai will discuss the factors influencing successful translation of the science into the clinic and how cost-effective solutions can expand the laboratory’s capabilities.

Learning Objectives:

• Pharmacogenetics as an important component of precision medicine
• Factors likely to influence faster and wider adoption of PGx
• Benefits of PGx sample analysis
• Methods to enable cost-effective PGx testing

Who Should Attend:

• Directors/CEOs of Toxicology Labs interested in expanding their business
• Lab Managers running PGx tests who wish to expand their PGx assay capabilities
• Pharmacogenetics researchers who want a powerful and flexible genetic analysis system for their research
• Directors/Managers of clinical research trials who wish to stratify trial participants
• Pharmacists interested in understanding how PGx can support drug choice and dosage

Speakers:

Dr. Stuart Scott, PhD

Assistant Professor Genetics and Genomic Sciences, Department of Genetics and Genomic Sciences

Icahn School of Medicine at Mount Sinai

Dr. Stuart Scott got his PhD from the University of Saskatchewan, Canada, under the mentorship of hematopathologist Dr. John F. DeCoteau. His interest in medical genetics and molecular pathology prompted postdoctoral American Board of Medical Genetics and Genomics (ABMGG) training in Clinical Molecular Genetics and Clinical Cytogenetics at the Mount Sinai Genetic Testing Laboratory (MGTL) and Board certification in both specialties. Dr. Scott is an Associate Director of the MGTL, which is a CLIA and New York State (NYS) approved and CAP accredited clinical genetics laboratory with Biochemical Genetics, Cytogenetics and Cytogenomics, and Molecular Genetics subdivisions. In the MGTL, he is involved in high-complexity clinical molecular testing, including array-based comparative genomic hybridization, exome sequencing, and pharmacogenetic testing. Dr. Scott is a Co-Investigator of the Institute for Personalized Medicine’s (IPM)-PGx and eMERGE-PGx programs by providing expertise in clinical genetics and implementing clinical pharmacogenetic testing at Mount Sinai. The clinical pharmacogenetics implementation projects at IPM are pre-emptively genotyping a panel of pharmacogenetic variants through the MGTL among prospectively enrolled patients at selected Mount Sinai clinics as well as patients enrolled in the BioMe biobank. This program seeks to develop process best practices for successful translation of pharmacogenomics and personalized medicine discoveries into clinical practice.

Divya Neelam, MSc

Manager, Applications Marketing

Agena Bioscience, Inc.

Divya Neelam, Manager of Applications Marketing at Agena Bioscience, oversees the commercial programs to support Agena’s scientific marketing initiatives. Over the past 9 years, Divya has worked closely with the users of the MassARRAY platform through her role as a bioinformatics and network support engineer and as an applications and technology scientist. She received her Master’s in Bioinformatics from Indiana University, Bloomington, Indiana.